Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $58.13 -4.28%
Financial Fact:
TOTAL OTHER INCOME (EXPENSE): -79.26K
Today's EPS Names:
SODI, PGR, OMID, More
Financial Fact:
TOTAL OTHER INCOME (EXPENSE): -79.26K
Today's EPS Names:
SODI, PGR, OMID, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($0.93), $0.11 better than the analyst estimate of ($1.04). Revenue for the quarter came in at $73.74 million versus the consensus estimate of $71.5 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AZZ, Inc. (AZZ) Tops Q2 EPS by 15c; raises guidance
- Solitron Devices, Inc. (SODI) Tops Q2 EPS by 60c
- Liquidia settles all litigation with United Therapeutics for $380.7M
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
